Range of cGVHD incidence following different initial GVHD prevention strategies. The bubble plot provides summary data on reported cGVHD incidence following varied HCT/GVHD prevention strategies. Each bubble represents an individual study, and size of the bubble reflects number of subjects reported for each. The reported incidence for each trial reflects a 2-year point estimate, although in a few cases, the point estimate is at 1 year, 18 months, or 3 years, depending on what was available from the appropriate publication. ABA, calcineurin inhibitor (CNI)/methotrexate (MTX)/abatacept; ATG, use of anti-thymocyte globulin in GVHD prevention approach; BM, bone marrow graft with CNI/MTX prophylaxis; CD20, depletion of CD20⁺ B cells; Graft, graft manipulation, exemplified by defined ratio of graft regulatory T cells and conventional T cells; Naïve, naïve T-cell depletion; PBSC, peripheral blood mobilized stem cells with CNI/MTX GVHD prophylaxis; PTCy, posttransplant cyclophosphamide-based prophylaxis; TCD, ex vivo T-cell depletion/CD34⁺ selection.